Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 7Recruiting 2Unknown 1Approved for marketing 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Thoracic 1NET 1Head & Neck 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 431Breast Neoplasms 300Neoplasms 297Colorectal Neoplasms 245Neoplasm Metastasis 193Ovarian Neoplasms 173Lung Neoplasms 151Prostatic Neoplasms 149Recurrence 147Pancreatic Neoplasms 143Multiple Myeloma 134Stomach Neoplasms 130Squamous Cell Carcinoma of Head and Neck 128Melanoma 123Endometrial Neoplasms 119Leukemia, Myeloid, Acute 114Advanced Solid Tumors 113Advanced Solid Tumor 111Triple Negative Breast Neoplasms 103Carcinoma, Hepatocellular 102Uterine Cervical Neoplasms 90Small Cell Lung Carcinoma 88Lymphoma, Non-Hodgkin 84Carcinoma, Renal Cell 72Lymphoma, Follicular 71Lymphoma 69Leukemia, Lymphocytic, Chronic, B-Cell 65Solid Tumor 64Lymphoma, Large B-Cell, Diffuse 64Esophageal Neoplasms 61

Interventions

repotrectinib 1ONC206 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × Neuroectodermal Tumors × Clear all
NCT03093116 2026-05-27

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04541082 2025-12-18

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Jazz Pharmaceuticals

Phase 1 Recruiting
102 enrolled
CNSSarcoma

Typical Teratoid Rhabdoid Tumor, Astrocytoma, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Oligodendroglioma, Pinealoma, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡